Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction

Eiki Goto, Jun Shimazaki, Y. u. Monden, Yoji Takano, Yukiko Yagi, Shigeto Shimmura, Kazuo Tsubota

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Obiective: We developed low-concentration homogenized castor oil eye drops for the treatment of patients with noninflamed obstructive meibomian gland dysfunction (MGD), a major cause of lipid -deficiency dry eye, and assessed the safety, stability, and efficacy of the eye drops. Design: Randomized, double-masked, placebo-controlled crossover clinical trial. Participants: Forty eyes of 20 patients with noninflamed MGD. Methods: After a preliminary study of eye drops containing castor oil, 2% castor oil and 5% polyoxyethylene castor oil (emulsifier) were mixed to formulate homogenized oil eye drops. The patients were assigned randomly to receive oil eye drops or placebo six times daily for 2 periods of 2 weeks each. Main Outcome Measures: At the end of each treatment period, we assessed symptoms, tear interference grade, tear evaporation, fluorescein and rose bengal scores, tear break-up time (BUT), and meibomian gland orifice obstruction. Safety and stability tests were also performed. Results: Symptom scores, tear interference grade, tear evaporation test results, rose bengal scores, tear BUT, and orifice obstruction scores after the oil eye drop period showed significant improvement compared with the results after the placebo period. No complications attributable to the eye drops were observed. The oil eye drops were stable when stored at 4°C. Conclusions: The results indicate that castor oil eye drops are effective and safe in the treatment of MGD. The possible mechanisms of this treatment are improvement of tear stability as a result of lipid spreading, ease of meibum expression, prevention of tear evaporation, and the lubricating effect of the oil eye drops.

Original languageEnglish
Pages (from-to)2030-2035
Number of pages6
JournalOphthalmology
Volume109
Issue number11
DOIs
Publication statusPublished - 2002 Nov 1

Fingerprint

Meibomian Glands
Castor Oil
Ophthalmic Solutions
Tears
Oils
Rose Bengal
Placebos
Lipids
Safety
Controlled Clinical Trials
Therapeutics
Fluorescein
Cross-Over Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. / Goto, Eiki; Shimazaki, Jun; Monden, Y. u.; Takano, Yoji; Yagi, Yukiko; Shimmura, Shigeto; Tsubota, Kazuo.

In: Ophthalmology, Vol. 109, No. 11, 01.11.2002, p. 2030-2035.

Research output: Contribution to journalArticle

Goto, Eiki ; Shimazaki, Jun ; Monden, Y. u. ; Takano, Yoji ; Yagi, Yukiko ; Shimmura, Shigeto ; Tsubota, Kazuo. / Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. In: Ophthalmology. 2002 ; Vol. 109, No. 11. pp. 2030-2035.
@article{85f133b138f441588ee4c789d645215a,
title = "Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction",
abstract = "Obiective: We developed low-concentration homogenized castor oil eye drops for the treatment of patients with noninflamed obstructive meibomian gland dysfunction (MGD), a major cause of lipid -deficiency dry eye, and assessed the safety, stability, and efficacy of the eye drops. Design: Randomized, double-masked, placebo-controlled crossover clinical trial. Participants: Forty eyes of 20 patients with noninflamed MGD. Methods: After a preliminary study of eye drops containing castor oil, 2{\%} castor oil and 5{\%} polyoxyethylene castor oil (emulsifier) were mixed to formulate homogenized oil eye drops. The patients were assigned randomly to receive oil eye drops or placebo six times daily for 2 periods of 2 weeks each. Main Outcome Measures: At the end of each treatment period, we assessed symptoms, tear interference grade, tear evaporation, fluorescein and rose bengal scores, tear break-up time (BUT), and meibomian gland orifice obstruction. Safety and stability tests were also performed. Results: Symptom scores, tear interference grade, tear evaporation test results, rose bengal scores, tear BUT, and orifice obstruction scores after the oil eye drop period showed significant improvement compared with the results after the placebo period. No complications attributable to the eye drops were observed. The oil eye drops were stable when stored at 4°C. Conclusions: The results indicate that castor oil eye drops are effective and safe in the treatment of MGD. The possible mechanisms of this treatment are improvement of tear stability as a result of lipid spreading, ease of meibum expression, prevention of tear evaporation, and the lubricating effect of the oil eye drops.",
author = "Eiki Goto and Jun Shimazaki and Monden, {Y. u.} and Yoji Takano and Yukiko Yagi and Shigeto Shimmura and Kazuo Tsubota",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S0161-6420(02)01262-9",
language = "English",
volume = "109",
pages = "2030--2035",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction

AU - Goto, Eiki

AU - Shimazaki, Jun

AU - Monden, Y. u.

AU - Takano, Yoji

AU - Yagi, Yukiko

AU - Shimmura, Shigeto

AU - Tsubota, Kazuo

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Obiective: We developed low-concentration homogenized castor oil eye drops for the treatment of patients with noninflamed obstructive meibomian gland dysfunction (MGD), a major cause of lipid -deficiency dry eye, and assessed the safety, stability, and efficacy of the eye drops. Design: Randomized, double-masked, placebo-controlled crossover clinical trial. Participants: Forty eyes of 20 patients with noninflamed MGD. Methods: After a preliminary study of eye drops containing castor oil, 2% castor oil and 5% polyoxyethylene castor oil (emulsifier) were mixed to formulate homogenized oil eye drops. The patients were assigned randomly to receive oil eye drops or placebo six times daily for 2 periods of 2 weeks each. Main Outcome Measures: At the end of each treatment period, we assessed symptoms, tear interference grade, tear evaporation, fluorescein and rose bengal scores, tear break-up time (BUT), and meibomian gland orifice obstruction. Safety and stability tests were also performed. Results: Symptom scores, tear interference grade, tear evaporation test results, rose bengal scores, tear BUT, and orifice obstruction scores after the oil eye drop period showed significant improvement compared with the results after the placebo period. No complications attributable to the eye drops were observed. The oil eye drops were stable when stored at 4°C. Conclusions: The results indicate that castor oil eye drops are effective and safe in the treatment of MGD. The possible mechanisms of this treatment are improvement of tear stability as a result of lipid spreading, ease of meibum expression, prevention of tear evaporation, and the lubricating effect of the oil eye drops.

AB - Obiective: We developed low-concentration homogenized castor oil eye drops for the treatment of patients with noninflamed obstructive meibomian gland dysfunction (MGD), a major cause of lipid -deficiency dry eye, and assessed the safety, stability, and efficacy of the eye drops. Design: Randomized, double-masked, placebo-controlled crossover clinical trial. Participants: Forty eyes of 20 patients with noninflamed MGD. Methods: After a preliminary study of eye drops containing castor oil, 2% castor oil and 5% polyoxyethylene castor oil (emulsifier) were mixed to formulate homogenized oil eye drops. The patients were assigned randomly to receive oil eye drops or placebo six times daily for 2 periods of 2 weeks each. Main Outcome Measures: At the end of each treatment period, we assessed symptoms, tear interference grade, tear evaporation, fluorescein and rose bengal scores, tear break-up time (BUT), and meibomian gland orifice obstruction. Safety and stability tests were also performed. Results: Symptom scores, tear interference grade, tear evaporation test results, rose bengal scores, tear BUT, and orifice obstruction scores after the oil eye drop period showed significant improvement compared with the results after the placebo period. No complications attributable to the eye drops were observed. The oil eye drops were stable when stored at 4°C. Conclusions: The results indicate that castor oil eye drops are effective and safe in the treatment of MGD. The possible mechanisms of this treatment are improvement of tear stability as a result of lipid spreading, ease of meibum expression, prevention of tear evaporation, and the lubricating effect of the oil eye drops.

UR - http://www.scopus.com/inward/record.url?scp=0036841406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036841406&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(02)01262-9

DO - 10.1016/S0161-6420(02)01262-9

M3 - Article

VL - 109

SP - 2030

EP - 2035

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -